These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 9780158)
1. Positive and negative regulation of human T cell activation mediated by the CTLA-4/CD28 ligand CD80. Boulougouris G; McLeod JD; Patel YI; Ellwood CN; Walker LS; Sansom DM J Immunol; 1998 Oct; 161(8):3919-24. PubMed ID: 9780158 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells. Manzotti CN; Tipping H; Perry LC; Mead KI; Blair PJ; Zheng Y; Sansom DM Eur J Immunol; 2002 Oct; 32(10):2888-96. PubMed ID: 12355442 [TBL] [Abstract][Full Text] [Related]
3. Integration of CD28 and CTLA-4 function results in differential responses of T cells to CD80 and CD86. Manzotti CN; Liu MK; Burke F; Dussably L; Zheng Y; Sansom DM Eur J Immunol; 2006 Jun; 36(6):1413-22. PubMed ID: 16708397 [TBL] [Abstract][Full Text] [Related]
4. T cells of staphylococcal enterotoxin B-tolerized autoimmune MRL-lpr/lpr mice require co-stimulation through the B7-CD28/CTLA-4 pathway for activation and can be reanergized in vivo by stimulation of the T cell receptor in the absence of this co-stimulatory signal. Zhou T; Weaver C; Linsley PS; Mountz JD Eur J Immunol; 1994 May; 24(5):1019-25. PubMed ID: 7514125 [TBL] [Abstract][Full Text] [Related]
5. CD28 engagement by B7/BB-1 induces transient down-regulation of CD28 synthesis and prolonged unresponsiveness to CD28 signaling. Linsley PS; Bradshaw J; Urnes M; Grosmaire L; Ledbetter JA J Immunol; 1993 Apr; 150(8 Pt 1):3161-9. PubMed ID: 7682233 [TBL] [Abstract][Full Text] [Related]
6. Role of CD80, CD86, and CTLA4 on mouse CD4(+) T lymphocytes in enhancing cell-cycle progression and survival after activation with PMA and ionomycin. Mukherjee S; Maiti PK; Nandi D J Leukoc Biol; 2002 Nov; 72(5):921-31. PubMed ID: 12429713 [TBL] [Abstract][Full Text] [Related]
7. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule. McLellan AD; Starling GC; Williams LA; Hock BD; Hart DN Eur J Immunol; 1995 Jul; 25(7):2064-8. PubMed ID: 7542604 [TBL] [Abstract][Full Text] [Related]
8. Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7. Damle NK; Klussman K; Leytze G; Myrdal S; Aruffo A; Ledbetter JA; Linsley PS J Immunol; 1994 Mar; 152(6):2686-97. PubMed ID: 7511623 [TBL] [Abstract][Full Text] [Related]
9. A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity. Chakrabarti R; Zhou ZF; Chang Y; Prud'homme GJ Vaccine; 2005 Aug; 23(37):4553-64. PubMed ID: 15919138 [TBL] [Abstract][Full Text] [Related]
10. Interference with CD28, CD80, CD86 or CD152 in collagen-induced arthritis. Limited role of IFN-gamma in anti-B7-mediated suppression of disease. Tellander AC; Pettersson U; Runström A; Andersson M; Michaëlsson E J Autoimmun; 2001 Aug; 17(1):39-50. PubMed ID: 11488636 [TBL] [Abstract][Full Text] [Related]
11. The B7/CD28/CTLA4 T-cell activation pathway. Implications for inflammatory lung disease. Green JM Am J Respir Cell Mol Biol; 2000 Mar; 22(3):261-4. PubMed ID: 10696061 [No Abstract] [Full Text] [Related]
12. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249 [TBL] [Abstract][Full Text] [Related]
13. Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population. Anderson DE; Bieganowska KD; Bar-Or A; Oliveira EM; Carreno B; Collins M; Hafler DA Nat Med; 2000 Feb; 6(2):211-4. PubMed ID: 10655112 [TBL] [Abstract][Full Text] [Related]
14. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. Freeman GJ; Lombard DB; Gimmi CD; Brod SA; Lee K; Laning JC; Hafler DA; Dorf ME; Gray GS; Reiser H J Immunol; 1992 Dec; 149(12):3795-801. PubMed ID: 1281186 [TBL] [Abstract][Full Text] [Related]
15. Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules. Mauri D; Wyss-Coray T; Gallati H; Pichler WJ J Immunol; 1995 Jul; 155(1):118-27. PubMed ID: 7541409 [TBL] [Abstract][Full Text] [Related]
16. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. Habib-Agahi M; Phan TT; Searle PF Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894 [TBL] [Abstract][Full Text] [Related]
17. CD28/CTLA-4 and CD80/CD86 families: signaling and function. Slavik JM; Hutchcroft JE; Bierer BE Immunol Res; 1999; 19(1):1-24. PubMed ID: 10374692 [TBL] [Abstract][Full Text] [Related]
18. NK cell triggering by the human costimulatory molecules CD80 and CD86. Wilson JL; Charo J; Martín-Fontecha A; Dellabona P; Casorati G; Chambers BJ; Kiessling R; Bejarano MT; Ljunggren HG J Immunol; 1999 Oct; 163(8):4207-12. PubMed ID: 10510357 [TBL] [Abstract][Full Text] [Related]
19. The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor. Freeman GJ; Cardoso AA; Boussiotis VA; Anumanthan A; Groves RW; Kupper TS; Clark EA; Nadler LM J Immunol; 1998 Sep; 161(6):2708-15. PubMed ID: 9743327 [TBL] [Abstract][Full Text] [Related]
20. CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. Sperling AI; Auger JA; Ehst BD; Rulifson IC; Thompson CB; Bluestone JA J Immunol; 1996 Nov; 157(9):3909-17. PubMed ID: 8892622 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]